TICKERNERD
Menu
MIRAMIRAHealthcare · Drug Manufacturers - General

MIRA Stock Forecast: MIRA Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Sept 2026
$0.88
+5.65% on the day

The 1 Wall Street analysts covering MIRA Pharmaceuticals, Inc. hold a median 12-month price target of $3.5 — +298.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 19 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$35.0M
Ticker Nerd rank
27 / 100
Median analyst target
$3.50
Analysts covering
1
Revenue$0.0
Operating income−$1.2M
Net income−$1.2M
Free cash flow−$1.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+16.7%
1M
+15.1%
YTD
−41.8%
1Y
−29.7%
From 52W high
−51.2%
From 52W low
+43.2%
$0.61
$1.80
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MIRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MIRA Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Volatility
71
Accruals
52
Revisions
45
Value
43
Momentum
35
Issuance
28
Growth
18
Quality
16

Size (85): Smaller than most of the companies we track.

Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MIRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MIRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26MIRAHigh $3.50Median $3.50Low $3.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $3.50Median $3.50High $3.50

The green dot is the last close — the median target sits +298.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026Maxim GroupInitiatesBuy$3.50
30 Sept 2024Rodman & RenshawInitiatesBuy$17
30 Sept 2024Rodman & RenshawInitiatesBuy—
5 Aug 2024Ascendiant CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MIRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MIRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 21 Sept 2026, MIRA Pharmaceuticals, Inc. returned −29.7% against +17.8% for the S&P 500, dividends included.

MIRA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26MIRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MIRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

MIRA Pharmaceuticals, Inc. (MIRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
−2.6×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−217.1%

Higher than 7% of US stocks

Return on assets
−129.5%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MIRA Pharmaceuticals, Inc. (MIRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MIRA Pharmaceuticals, Inc. has a market value of $35.0M and an enterprise value of $26.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$9.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$4.6M.

  • Shares outstanding: 42.0M.

  • Trailing P/E: −0.6×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • MIRA Pharmaceuticals, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Sept 2026

Data provided by Twelve Data

Peers

MIRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
MIRAMIRA Pharmaceuticals, Inc.$35.0M
27
SCLXScilex Holding Co.$35.5M
13
NSRXNasus Pharma Ltd.$41.3M
17
FLNAFilana Therapeutics, Inc.*$35.1M
60
DCGODocGo, Inc.*$35.1M
35
PETSPetMed Express, Inc.*$34.4M
39
CCELCryo-Cell International, Inc.*$35.5M
77

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MIRA Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MIRA news & analysis

MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review

GlobeNewsWire · 17 Sept 2026positive

Following FDA review and comments, MIRA Pharmaceuticals has submitted its Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) for Institutional Review Board review at a leading cancer research institution.

Why it matters — This marks progress in advancing Ketamir-2, a key pipeline candidate, toward a Phase 2a clinical trial for CIPN.

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

GlobeNewsWire · 1 Sept 2026positive

MIRA Pharmaceuticals announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of its non-opioid oral candidate MIRA-55 in rats and dogs, advancing the drug toward an IND for inflammatory pain.

Why it matters — The favorable toxicology results support MIRA-55's progression toward an Investigational New Drug application, marking a key development milestone for the company's non-opioid pipeline.

MIRA Reports Positive 7-Day Dog Study Results for SKNY-1

GlobeNewsWire · 6 Aug 2026positive

MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of SKNY-1, an obesity treatment candidate, in Beagle dogs. The study showed dose-dependent systemic exposure and rapid absorption, helping de-risk dose selection and supporting advancement toward GLP toxicology studies and IND-enabling development.

Why it matters — The results support SKNY-1's regulatory pathway and de-risk dose selection as MIRA moves the candidate toward toxicology studies and IND-enabling development.

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

GlobeNewsWire · 30 July 2026positive

MIRA Pharmaceuticals announced it has advanced its two lead preclinical programs, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders, through formulation optimization, CMC activities, manufacturing development, and exploratory non-GLP toxicology and toxicokinetic studies toward IND-enabling studies.

Why it matters — The advancement of both preclinical programs toward IND-enabling studies signals progress in MIRA's pipeline toward potential clinical trials.

FAQ

Frequently asked questions about MIRA stock

What is the MIRA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering MIRA Pharmaceuticals, Inc. have a median 12-month price target of $3.5, with estimates ranging from $3.5 to $3.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MIRA stock a buy right now?

Of the 1 analysts covering MIRA Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MIRA Pharmaceuticals, Inc. 27 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MIRA?

As at 19 Sept 2026, MIRA Pharmaceuticals, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will MIRA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +298.2% from the last close, and Ticker Nerd's factor model ranks MIRA Pharmaceuticals, Inc. 27 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MIRA stock forecast for 2030?

No analyst covering MIRA Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $3.5 over the next 12 months.

How has MIRA stock performed over the past year?

MIRA Pharmaceuticals, Inc. returned -29.7% over the 12 months to 21 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MIRA Pharmaceuticals, Inc. do?

Mira Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for neurologic, neuropsychiatric, metabolic, and pain-related disorders.

What is the latest news on MIRA?

The most recent item we track (GlobeNewsWire, 17 Sept 2026): "MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review". Following FDA review and comments, MIRA Pharmaceuticals has submitted its Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) for Institutional Review Board review at a leading cancer research institution.

Company

About MIRA Pharmaceuticals, Inc.

Mira Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for neurologic, neuropsychiatric, metabolic, and pain-related disorders. The company’s pipeline centers on investigational drug candidates such as Ketamir-2, MIRA-55, and SKNY-1, which are being evaluated for conditions including neuropathic and inflammatory pain, anxiety, cognitive impairment, obesity, addiction-related disorders, and smoking cessation. Mira Pharmaceuticals concentrates on early-stage drug discovery and development, with an emphasis on small-molecule therapies designed to address unmet medical needs across the central nervous system and related treatment areas. The company operates as a specialized developer within the pharmaceutical sector, with its current work centered on advancing experimental treatments rather than commercial products.

CEO Mr. Erez Aminov · United States · https://mirapharmaceuticals.com